Image
Join the Midwest AETC for a 2-part series on Long-Acting Injectable (LAI) medications for HIV PrEP. The first session involves an industry talk with two Medical Scientist Liaisons who will share the science and research behind their medications - Lenacapavir and Cabotegravir. This program offers a unique opportunity to engage directly with the industry experts involved in bringing these critical new prevention tools to the forefront of HIV care.
Objectives
- Explain the mechanism of action for long-acting injectable medications for HIV PrEP
- Understand the prescribing information for long-acting injectable medications for HIV PrEP
- Summarize clinical trial data that lead to FDA approval of long-acting injectables for HIV PrEP
Speakers
Nicholas Olson, Pharm.D., BCACP, FPSW
Senior Medical Scientist- HIV Medical Affairs
Gilead Sciences, Inc.
Ryan Kates, Pharm.D., BCACP
Medical Science Liaison-Midwest ViiV Healthcare